<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00269880</url>
  </required_header>
  <id_info>
    <org_study_id>CR006262</org_study_id>
    <nct_id>NCT00269880</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Clinical Outcomes Following Percutaneous Coronary Intervention in Patients Treated With an Abciximab Bolus Plus 12-Hour Infusion Given With Either Standard-Dose Weight-Adjusted Heparin or Low-Dose Weight-Adjusted Heparin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of abciximab, an
      anti-platelet therapy, versus placebo in patients undergoing percutaneous coronary
      intervention when administered in combination with two different heparin regimens. Please see
      attached results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial comparing the efficacy and
      safety of abciximab, an anti-platelet therapy, in combination with two different heparin
      regimens in patients undergoing percutaneous coronary intervention. Patients will be randomly
      assigned to one of three treatment groups: abciximab/low-dose weight-adjusted heparin,
      abciximab/standard-dose weight-adjusted heparin, or placebo/standard-dose weight-adjusted
      heparin. The primary outcomes of the study include the number of deaths, myocardial
      infarctions, or repeat revascularizations within 6 months, and the number of deaths,
      myocardial infarctions, or severe myocardial ischemia leading to urgent repeat percutaneous
      coronary intervention or urgent coronary artery bypass surgery within 30 days. Please see
      attached results.

      Abciximab bolus plus 12-hour infusion with standard-dose weight-adjusted heparin; Abciximab
      bolus plus 12-hour infusion with low-dose weight-adjusted heparin; Placebo bolus plus 12-hour
      infusion with standard-dose weight-adjusted heparin
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1995</start_date>
  <completion_date type="Actual">December 1995</completion_date>
  <primary_completion_date type="Actual">December 1995</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death, myocardial infarction, or repeat revascularization within 6 months</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death, myocardial infarction, or severe myocardial ischemia leading to urgent repeat percutaneous coronary intervention or urgent coronary artery bypass surgery within 30 days</measure>
    <time_frame>Up to 30 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic outcome; death, MI or target vessel revascularization within 6 months; death or MI within 6 months; health economic analyses</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2792</enrollment>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>Placebo and Standard Dose of Heparin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abciximab and Low Dose of Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abciximab and Standard Dose Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.</description>
    <arm_group_label>Placebo and Standard Dose of Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.</description>
    <arm_group_label>Placebo and Standard Dose of Heparin</arm_group_label>
    <arm_group_label>Abciximab and Low Dose of Heparin</arm_group_label>
    <arm_group_label>Abciximab and Standard Dose Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <description>Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.</description>
    <arm_group_label>Abciximab and Low Dose of Heparin</arm_group_label>
    <arm_group_label>Abciximab and Standard Dose Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred for elective or urgent percutaneous coronary intervention with an
             FDA-approved device

          -  Having a target artery (native or graft) stenosis of 60% by visual estimation

        Exclusion Criteria:

          -  Patients with unstable angina/non-Q-wave myocardial infarction meeting EPIC criteria
             within the previous 24 hours, or with acute Q-wave myocardial infarction meeting EPIC
             criteria with onset of chest pain within previous 24 hours

          -  With active internal bleeding, having a condition that may increase the risk of
             bleeding, or currently receiving administration of oral anticoagulants at the time of
             study entry

          -  With confirmed hypertension with systolic blood pressure &gt;180 mm Hg or diastolic blood
             pressure &gt;100 mm Hg

          -  Having had a percutaneous coronary intervention within the previous 3 months

          -  Having an unprotected left main coronary artery stenosis &gt; 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=213&amp;filename=CR017452_CSR.pdf</url>
    <description>A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma</description>
  </link>
  <results_reference>
    <citation>Lincoff AM, Mark DB, Tcheng JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. 2000 Dec 12;102(24):2923-9.</citation>
    <PMID>11113041</PMID>
  </results_reference>
  <results_reference>
    <citation>Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. 1999 Apr 20;99(15):1951-8.</citation>
    <PMID>10208997</PMID>
  </results_reference>
  <results_reference>
    <citation>EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997 Jun 12;336(24):1689-96.</citation>
    <PMID>9182212</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2005</study_first_submitted>
  <study_first_submitted_qc>December 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2005</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angioplasty, Transluminal, Percutaneous coronary</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

